AT&S Austria Technologie & Systemtechnik (ATS.VI) — Graham Screen #

Layer: L8-Substrate (ABF IC Substrate / Advanced PCB) Date: 2026-05-28 Screener: shr-020 same-day check + full Graham 7 filters

PRICE SNAPSHOT #

CRITICAL FLAG: This is emphatically NOT a laggard. AT&S is at 52-week highs after a +327% YTD surge and +693% 52-week return. The thesis premise ("may have lagged the broader rally") is the opposite of reality. The stock went from distressed (~EUR 15) to near-all-time-high (~EUR 147) in 12 months. The investment window for any distressed value entry has already closed.

Catalyst for rally: FY2025/26 annual results (May 21, 2026) + management board announcement (May 20) of AI substrate capacity expansion in Chongqing backed by long-term customer agreements. The market recognized the cyclical inflection well before the results were published.

1. COMPANY PROFILE #

AT&S Austria Technologie & Systemtechnik AG (Vienna Stock Exchange: ATS) is an Austrian manufacturer of advanced printed circuit boards and IC substrates. Core segments: Microelectronics (IC substrates for semiconductors/AI), Electronics Solutions (HDI PCBs), Others. Key production sites: Leoben/Fehring (Austria), Shanghai/Chongqing (China), Kulim (Malaysia), Nanjangud (India). Founded 1987. ~13,064 employees. Fiscal year ends March 31.

Positioned in the supply chain as an ABF (Ajinomoto Build-up Film) substrate manufacturer — the critical interconnect layer between advanced chips (Intel, AMD, Nvidia-ecosystem) and PCB assemblies. This is a high-barrier, capital-intensive niche adjacent to TSMC's packaging ecosystem.

2. FINANCIALS — 5-YEAR HISTORY #

Income Statement (FY ends March 31, EUR millions) #

*FY2025 EBITDA of EUR637M is distorted by EUR182M "unusual items" (asset sale proceeds — Ansan Korea plant). Normalized EBITDA FY2025 = EUR451M per company disclosure.

Note on yfinance data: yfinance's "current" trailing EPS of EUR3.29 is stale/incorrect — it appears to blend FY24/25 data. The actual FY2025/26 reported EPS is -EUR1.11 (net loss EUR25.6M). All Graham calculations use actual reported figures.

Cash Flow (EUR millions) #

FCF Trajectory: Three consecutive years of negative FCF (FY2023-2025) from the EUR2.3B Kulim+Chongqing capacity buildout. FY2026 marks the inflection — capex dropped to EUR178M (from EUR1.1B peak), operating FCF turned positive at EUR235M. FY2027 guided capex ~EUR400M (customer-financed Chongqing AI substrate expansion — importantly, this is backed by long-term offtake agreements, not speculative).

Balance Sheet (EUR millions, as of March 31) #

Leverage trajectory is deteriorating on reported basis (0.4x → 3.2x ND/EBITDA over 4 years), though company targets "significantly below 3x" by end of FY2026/27 as Chongqing ramp generates EBITDA.

3. (a) DEBT STRUCTURE AND CONVERTIBLE MECHANICS (shr-039) #

Existing Debt Stack #

KEY RISK — First Call January 2027: The EUR350M hybrid bond (5% perpetual) has its first call date in January 2027. If AT&S does not call it, the coupon steps up (typically +25bps per period on hybrid structures). This creates a refinancing overhang in H2 2026. The new hybrid convertible/hybrid bond issuance (up to EUR500M announced May 20, 2026) is specifically designed to refinance this and strengthen capital.

Proposed New Capital Markets Instruments (May 20, 2026 announcement) #

• Hybrid Convertible Bond: up to EUR400M, deeply subordinated perpetual with early redemption option. Converts into new ordinary shares at a conversion price to be set at market conditions at issuance time.
• Hybrid Bond: up to EUR400M, same subordinated perpetual structure without equity conversion.
• Combined cap: EUR500M total across both instruments.
• Settlement: Q2 or Q3 2026. Institutional only. EUR100,000 denomination.

Dilution Analysis per shr-039 #

• Authorized new shares for convertible: up to 19,425,000 shares (AGM July 4, 2024) — 50% of current shares outstanding at maximum authorization.
• Actual dilution depends on conversion price (not yet set): at EUR150 conversion price and EUR400M deal, ~2.67M new shares = 6.9% dilution. At EUR100 conversion price, 4.0M shares = 10.3% dilution.
• The EUR400M maximum convertible capacity represents a 7-10% dilution ceiling, NOT the 50% maximum authorization.
• Structural ceiling per shr-039: A EUR400M convertible at current market price (~EUR140) would create ~2.86M new shares (7.4%). As the stock approaches conversion price on a rally, incremental dilution pressure kicks in. At current price, this is a moderate risk — manageable for a EUR5.4B market cap company.
• However: The hybrid instrument (non-convertible) creates ongoing cash coupon outflow. Combined interest burden (existing EUR350M@5% = EUR18M + new EUR400M@~5% = EUR20M + senior/bank debt interest ~EUR95M) = potentially EUR133M+ annual interest expense in FY2026/27.

4. (b) EBITDA vs INTEREST COVERAGE #

FY2025/26 (ended March 2026):

• EBITDA: EUR418M
• Estimated interest expense: ~EUR130M
• EBITDA/Interest: ~3.2x — thin but not crisis-level
• EBIT estimated at ~EUR238M (EBITDA EUR418M – D&A ~EUR180M)
• EBIT/Interest: ~1.8x — this is the critical concern. Below 2x EBIT coverage is a yellow flag for bond covenants.

FY2026/27 (guidance):

• Revenue: EUR2.1–2.4B (midpoint EUR2.25B), +34% growth
• EBITDA margin: 25–29% (midpoint 27%) → EBITDA EUR607M
• Post-new-bond interest: est EUR130–145M
• EBITDA/Interest FY26/27: ~4.4x — materially better
• EBIT (at ~20% EBIT margin on rev): ~EUR450M → EBIT/Interest: ~3.2x → comfortable territory

The FY2026/27 guidance is the key deleveraging milestone — if management delivers EUR2.1–2.4B revenue with 25–29% EBITDA margin AND capex remains at ~EUR400M (partially customer-financed), the leverage ratio improves toward 2x ND/EBITDA within 12 months.

5. (c) FCF TRAJECTORY AND CAPEX DIGESTION #

*FY2027 capex is higher than FY2026 but materially below the EUR1B+ peak, and critically the Chongqing expansion is customer-financed via long-term supply agreements. This structurally derisks the capex — AT&S is spending on behalf of a committed buyer.

Verdict on capex digestion: The Kulim Malaysia plant is now ramping (HDI PCBs + substrate capability). Chongqing is the AI substrate expansion. The heavy investment phase is behind them; FY2026 marks the beginning of the harvest phase. FCF should turn sustainably positive in FY2027.

Cost reduction: EUR170M cost reduction achieved in FY2025/26, exceeding target of EUR160M. This is structural margin improvement, not one-time.

6. (d) DIVIDEND STATUS #

• Dividend cut: Zero dividend for FY2024/25 (cut from EUR0.40 in FY2022/23).
• Zero again: Management board proposes zero dividend for FY2025/26.
• Last meaningful dividend: EUR1.10/share in FY2019 (pre-Kulim buildout). EUR0.40 in FY2022/23 was a token payout.
• Rationale: Capital preservation during leverage ramp. Hybrid bond coupon deferral possible (perpetual structure). No near-term dividend resumption likely until ND/EBITDA sustainably <2.5x.

7. (e) KULIM / CHONGQING RAMP PROGRESS #

Kulim (Malaysia): Operational. Primarily HDI and rigid-flex PCBs. The Ansan (Korea) asset sale (EUR353M proceeds in FY2024/25) funded balance sheet repair. Kulim is now the designated Asian manufacturing hub for non-substrate PCB products.

Chongqing (China): The AI substrate growth driver. Management Board approved Chongqing expansion on May 20, 2026 (same day as hybrid bond announcement). Key details:

• Investment in "high double-digit million EUR" range (not the EUR billions of Kulim buildout)
• Backed by long-term customer agreements for high-end IC substrates
• Expected EBIT benefit "of similar magnitude" (i.e., tens of millions EUR in FY2027)
• Revenue growth driver: FY2026/27 guidance 30–35% growth is primarily Chongqing AI substrate ramp

Customer concentration risk: Not explicitly disclosed in public filings. AT&S has historically concentrated substrate revenue in a small number of large customers (Intel, AMD ecosystem and potentially Nvidia supply chain via their ODM customers). This is structurally similar to other substrate manufacturers. The "long-term customer agreements" language for Chongqing provides revenue visibility but means single customer concentration if the relationship deteriorates.

8. (f) CUSTOMER CONCENTRATION #

No explicit breakdown in public sources. However from industry context:

• IC substrate customers globally are 5–10 large hyperscalers and chipmakers (Intel, AMD, Nvidia, Qualcomm, Broadcom)
• AT&S is significantly smaller than Ibiden, Shinko (both Japanese substrate giants)
• Customer-financed expansion = at least one major committed buyer, likely a single strategic relationship
• This is a KEY undisclosed risk — if the anchor Chongqing customer cancels or defers, the FY2027 thesis collapses

9. GRAHAM 7 FILTER SCREEN #

AT&S uses a March 31 fiscal year end. FY2025/26 = April 2025 – March 2026.

Graham Score: 1/7. Only size passes.

10. GRAHAM INTRINSIC VALUE SENSITIVITY TABLE (shr-003, shr-012) #

Trailing EPS (FY2025/26): -EUR1.11 → Graham IV formula inapplicable on trailing basis

Forward EPS consensus (FY2026/27, 4 analysts): EUR3.265

Bond yield (AAA/European approx): 4.5%

Implied growth at EUR140.20 (forward P/E basis): Forward P/E = 42.9x → implied Graham growth = (42.9 - 8.5) / 2 = 17.2%/yr

Interpretation: The stock requires 17%+ sustained annual EPS growth (Graham formula) for the current price to be justified. FY2027 guidance is for 30-35% revenue growth, which at 25-29% EBITDA margins could deliver EPS in the EUR3-5 range. But this is one year — sustaining 17%/yr for a decade requires AT&S to continuously win high-end substrate contracts in a market dominated by Japanese incumbents (Ibiden, Shinko). That is a growth stock assumption, not a Graham value assumption.

The only growth scenario where EUR140 makes sense on Graham formula is 20%+ sustained growth — barely above current price, with a wafer-thin margin of safety. This is precisely the shr-004 Growth Stock Addendum territory.

11. ANALYST CONSENSUS #

This is the single most alarming valuation signal. AT&S is trading 17% above even the most bullish analyst's price target (EUR120) and 59% above the consensus mean (EUR88). The stock has massively outrun analyst models. This either means (a) analysts have not yet updated their models post-May earnings, or (b) the market is pricing a narrative premium the fundamentals don't yet support.

Given that the May 20-21 results were only 7 days ago and the stock surged +50% in the week post-results, analyst upgrades and target revisions are likely but not yet reflected in the EUR88 mean. However, even revised targets of EUR120-150 would place the stock at fair-to-slightly-expensive territory, not cheap.

12. DISTRESSED-CREDIT vs GRAHAM VALUE DISTINCTION #

The distressed value thesis was valid in June 2025 (stock at EUR15-17). At that price:

• P/B was ~0.2x (deeply below book)
• ND/EBITDA recovery was plausible once capex peaked
• Dividend restoration possible post-deleveraging
• Graham formula MIGHT have worked at g=0% with normalised EPS

None of that applies today at EUR140. The stock is a different investment case:

13. shr-020 RED FLAG CHECK #

Aggregate shr-020 assessment: 5 REDs, 2 AMBERs, 2 UNKNOWNs. This is not a buy candidate.

14. VERDICT #

🔴 HARD PASS — NOT A GRAHAM VALUE CANDIDATE AT EUR140 #

Primary reason: The investment opportunity has already been captured by the market. AT&S was a distressed value play at EUR15-17 (Jun 2025). At EUR140, it is a momentum/growth stock trading at:

• 43x forward earnings
• 9x book value
• 59% above analyst consensus price target
• 17% above the most bullish analyst's target

Balance sheet: The balance sheet is improving but not repaired. ND/EBITDA 3.2x with EBIT/interest coverage of ~1.8x is suboptimal. The EUR350M hybrid bond first call in January 2027 creates a near-term refinancing event. The new EUR500M hybrid/convertible issuance will extend maturities but adds coupon burden.

Convertible mechanics (shr-039): At EUR400M convert, dilution is manageable (7-10%) at this price level, but the convert acts as a ceiling near conversion price on future rallies. More importantly, the perpetual hybrid bond structure creates ongoing cash coupon drain (EUR38M+/yr for existing + new hybrids) on top of ~EUR95M senior/bank interest.

Graham Growth Addendum (shr-004): This is the only framework where the stock could theoretically work. At EUR3.265 forward EPS and FY2027 guidance for 30-35% revenue growth with 25-29% EBITDA margins, future EPS could reach EUR5-8 in FY2028-2029 if Chongqing ramp delivers. But: (1) the market has already priced this in, (2) Japanese substrate incumbents (Ibiden, Shinko) have cost/quality advantages, (3) customer concentration is undisclosed, (4) capex will re-accelerate to EUR400M+ in FY2027 as AI substrate demand scales.

If re-examining at EUR50-70: That would be the growth stock entry zone — forward P/E of 15-21x on EUR3.27 EPS with 17-21% implied growth. Still not Graham defensive, but the Growth Addendum would support it. Current price is 2-3x that level.

Deleveraging Trigger (if monitoring for future opportunity) #

If the FY2026/27 results (May 2027) show:

1. ND/EBITDA confirmed <2.5x
2. EPS >EUR5.00 (FY2027/28 trajectory)
3. Dividend resumed or explicitly guided
4. Chongqing customer named and multi-year contracted

...then AT&S at EUR50-80 in a market selloff would merit a full re-screen. Do not chase at EUR140.

SOURCES CONSULTED #

• yfinance (ATS.VI): price history, financials FY2022-FY2025
• AT&S FY2025/26 annual results (May 21, 2026) via Finanzwire
• AT&S hybrid bond announcement (May 20, 2026) via EQS/Finanzwire
• AT&S hybrid bond 2022 (EUR350M@5%, Jan 2027 first call) via ats.net
• Alpha Spread investor relations (Q3 FY2026 balance sheet data)
• yfinance analyst estimates (5 analysts, mean PT EUR88.12)

VERDICT LINE: 🔴 HARD PASS. AT&S is at 52-week highs (+327% YTD), trades 59% above analyst consensus PT (EUR88), scores 1/7 on Graham defensive filters, has negative trailing EPS (FY25/26: -EUR1.11), ND/EBITDA 3.2x, EBIT/interest ~1.8x, and an EUR350M hybrid bond first call in January 2027 requiring refinancing. The distressed value window was EUR15-17 in June 2025 — that opportunity is gone. Re-screen only if stock corrects to EUR50-70 AND FY2027 EBITDA confirms the 25-29% margin trajectory.